Anova and Nouveau Biosciences partner on Phase 1 Kromastat trial in T-cell lymphoma
Anova will manage Kromastat’s first-in-human Phase 1 trial as Nouveau Biosciences tests a nanoparticle approach in T-cell lymphomas.
Pharma & Biotech
Pharma & Biotech
GemPharmatech just added a humanized liver model, but can it close the clinical translation gap?
GemPharmatech and Humlab Global expand access to humanized mouse models, but validation and adoption will determine their clinical value.
Pharma & Biotech
FDA gives Genentech’s Gazyva Priority Review for primary membranous nephropathy
FDA Priority Review puts Genentech’s Gazyva on a November decision path in primary membranous nephropathy after the Phase III MAJESTY win.
Pharma & Biotech
Can VDPHL01 carry its male-trial momentum into women? Veradermics is about to show the data
See why Veradermics’ Study 207 female data could shape VDPHL01 dose selection, safety expectations and its Phase 3 clinical strategy.
Medical Devices & Diagnostics
Why Leica Biosystems wants StatLab’s pathology consumables before AI diagnostics scale
Leica Biosystems will acquire StatLab to deepen its pathology workflow portfolio as Danaher targets lab standardization and recurring sales.
Pharma & Biotech
Why Kelun-Biotech’s latest sac-TMT Phase III result could matter more than the headline suggests
Kelun-Biotech reports improved Phase III PFS with sac-TMT plus pembrolizumab, while survival and detailed safety data remain pending.
Medical Devices & Diagnostics
Castle Biosciences wins crucial New York access, but can AdvanceAD-Tx overcome the reimbursement test?
Castle Biosciences gains New York approval for AdvanceAD-Tx, expanding access while reimbursement and clinical adoption remain decisive.
Pharma & Biotech
How the BOND trial will test prenatal mental health support for congenital heart disease
The BOND trial will test HeartGPS and breastfeeding support for families affected by critical congenital heart disease across 17 US centers.
Pharma & Biotech
Senhwa’s NT$500m GEM deal sounds like fresh funding, but the structure is more complicated
Senhwa formalises a NT$500 million GEM share purchase pact, but direct funding, dilution and pipeline execution remain the decisive questions.
Pharma & Biotech
What the zemprocitinib enrollment milestone means for Lynk Pharmaceuticals’ late-stage pipeline
Lynk Pharmaceuticals completes Phase III zemprocitinib enrollment as ASAS40 efficacy, long-term safety and China filing tests move closer.